In the present study,we discussed the drug-induced liver injury caused by Chinese patent medicines containing Polygonum multiflorum to provide a reference for clinical rational drug use of Polygonum multiflorum and it...In the present study,we discussed the drug-induced liver injury caused by Chinese patent medicines containing Polygonum multiflorum to provide a reference for clinical rational drug use of Polygonum multiflorum and its preparations.One case of long-term taking Jingwu capsule and Huolisu oral liquid,which led to the drug-induced liver injury,was reported.The other case took Runzaozhiyang capsule for a long time,which also led to drug-induced liver injury.Jingwu capsule,Huolisu oral liquid,and Runzaozhiyang capsule all contained Polygonum multiflorum,which could result in liver injury when used long-term.Moreover,we explored the clinical features and toxicity of liver damage induced by Polygonum multiflorum.Liver damage in serum transaminase was significantly increased,and the increasing rate of ALT was more than that of AST.Jaundice appeared obviously.The liver damage mechanisms included drug metabolism,immune response,physical fitness,and many other reasons.Corresponding suggestions on rational use of Polygonum multiflorum and its preparations were presented.The dosage and period should be regulated.The index of liver function should be monitored during the medication periods.Collectively,patients with a history of liver disease or a history of allergies should pay more attention when using the above-mentioned drugs.展开更多
目的评估复方首乌口服液治疗斑秃的临床效果和安全性。方法采用随机、平行对照的研究方法,将214例斑秃患者随机分为复方首乌口服液组(试验组)和活力苏口服液组(对照组),每组107例。治疗8周后,比较两组的疗效和不良反应发生情况。结果复...目的评估复方首乌口服液治疗斑秃的临床效果和安全性。方法采用随机、平行对照的研究方法,将214例斑秃患者随机分为复方首乌口服液组(试验组)和活力苏口服液组(对照组),每组107例。治疗8周后,比较两组的疗效和不良反应发生情况。结果复方首乌口服液组93例和活力苏口服液组94例完成研究。患者口服复方首乌口服液有效率为81.72%(76/93),口服活力苏口服液有效率为77.66%(73/94),两组有效率无显著性差异(P>0.05)。复方首乌口服液组的疗效指数为(30.07±18.52)%,活力苏口服液组的疗效指数为(29.22±22.02)%,两组疗效指数无显著性差异(P>0.05)。复方首乌口服液组治疗前平均皮肤病生活质量指数(dermatology life quality index,DLQI)评分为(5.14±2.43)分,治疗后平均评分为(2.41±3.03)分,DLQI评分治疗后较治疗前明显降低(P<0.01);活力苏口服液组的治疗前平均DLQI评分评分为(5.66±4.78)分,治疗后平均评分为(2.04±2.47)分,DLQI评分治疗后较治疗前亦明显降低(P<0.01);两组DLQI比较,差异无统计学意义(P>0.05)。复方首乌口服液组的不良反应发生率为1.87%(2/107),活力苏口服液组无不良反应,两组间差异无统计学意义(P>0.05)。结论复方首乌口服液对斑秃有较好疗效,与活力苏口服液疗效相当,且患者耐受性好,安全性高。展开更多
基金Traditional Chinese Medical Science and Technology Projects of Zhejiang Province(Grant No.2016ZQ017 and 2015ZB044)Clinical pharmacy of TCM in the 13th five years plan of Zhejiang Administration of traditional Chinese Medicine(Zhejiang health office TCM(2019)No.1)the Clinical Pharmacy Research Fund of Chinese Integrative Medicine Association of Zhejiang Province(Grant No.2013LYSX018)。
文摘In the present study,we discussed the drug-induced liver injury caused by Chinese patent medicines containing Polygonum multiflorum to provide a reference for clinical rational drug use of Polygonum multiflorum and its preparations.One case of long-term taking Jingwu capsule and Huolisu oral liquid,which led to the drug-induced liver injury,was reported.The other case took Runzaozhiyang capsule for a long time,which also led to drug-induced liver injury.Jingwu capsule,Huolisu oral liquid,and Runzaozhiyang capsule all contained Polygonum multiflorum,which could result in liver injury when used long-term.Moreover,we explored the clinical features and toxicity of liver damage induced by Polygonum multiflorum.Liver damage in serum transaminase was significantly increased,and the increasing rate of ALT was more than that of AST.Jaundice appeared obviously.The liver damage mechanisms included drug metabolism,immune response,physical fitness,and many other reasons.Corresponding suggestions on rational use of Polygonum multiflorum and its preparations were presented.The dosage and period should be regulated.The index of liver function should be monitored during the medication periods.Collectively,patients with a history of liver disease or a history of allergies should pay more attention when using the above-mentioned drugs.
文摘目的评估复方首乌口服液治疗斑秃的临床效果和安全性。方法采用随机、平行对照的研究方法,将214例斑秃患者随机分为复方首乌口服液组(试验组)和活力苏口服液组(对照组),每组107例。治疗8周后,比较两组的疗效和不良反应发生情况。结果复方首乌口服液组93例和活力苏口服液组94例完成研究。患者口服复方首乌口服液有效率为81.72%(76/93),口服活力苏口服液有效率为77.66%(73/94),两组有效率无显著性差异(P>0.05)。复方首乌口服液组的疗效指数为(30.07±18.52)%,活力苏口服液组的疗效指数为(29.22±22.02)%,两组疗效指数无显著性差异(P>0.05)。复方首乌口服液组治疗前平均皮肤病生活质量指数(dermatology life quality index,DLQI)评分为(5.14±2.43)分,治疗后平均评分为(2.41±3.03)分,DLQI评分治疗后较治疗前明显降低(P<0.01);活力苏口服液组的治疗前平均DLQI评分评分为(5.66±4.78)分,治疗后平均评分为(2.04±2.47)分,DLQI评分治疗后较治疗前亦明显降低(P<0.01);两组DLQI比较,差异无统计学意义(P>0.05)。复方首乌口服液组的不良反应发生率为1.87%(2/107),活力苏口服液组无不良反应,两组间差异无统计学意义(P>0.05)。结论复方首乌口服液对斑秃有较好疗效,与活力苏口服液疗效相当,且患者耐受性好,安全性高。
